Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864969 | 0.94 | SCD (0.42) | SCDAOC3PPARACHRM4EPHX2 | |
| SCHEMBL4988043 | 0.93 | PPARA (0.42) | SCDPPARACHRM4EPHX2NR1H4 | |
| SCHEMBL4985031 | 0.91 | ALDH1A1 (0.42) | NAMPTSCDCHRM4 | |
| SCHEMBL4988574 | 0.91 | AOC3 (0.43) | NAMPTSCDAOC3PPARACHRM4 | |
| SCHEMBL4990336 | 0.90 | SCD (0.38) | KDRSCDAOC3PPARA | |
| SCHEMBL4991267 | 0.90 | PPARA (0.42) | SCDAOC3PPARA | |
| SCHEMBL4986164 | 0.89 | AOC3 (0.35) | AOC3PPARA | |
| SCHEMBL4871391 | 0.88 | AOC3 (0.39) | AOC3 | |
| SCHEMBL4990577 | 0.88 | SCD (0.38) | SCDAOC3 | |
| SCHEMBL4986021 | 0.87 | AOC3 (0.34) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | NAMPT 738/4885KDR 50/4885SCD 715/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | NAMPT 734/4885KDR 56/4885SCD 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.